Lipid-lowering therapy intensification
Lipid-lowering therapy intensification has been studied in 1 paper since 2026: 1 observational study in people; 1 in the past year. The newest paper, Mar 18, 2026: “Association Between Lipoprotein(a) Testing, Lipid-Lowering Therapy Intensification, and Low-Density Lipoprotein Cholesterol Goal Attainment: Findings From the Veterans Affairs Health System”.
1 paper studies it2 findingsUpdated
See all 1 papers on lipid-lowering therapy intensification
At a glance
The findings reach people, from one lab or study. 1 lab in 1 country.
“Lp(a) testing was associated with greater LLTI (odds ratio [OR], 2.11 [95% CI, 1.95-2.29])”
None of its findings points the other way.
- 1 lab in 1 country
- 2 of 2 findings with company ties
- Humans1
What is lipid-lowering therapy intensification linked with?
2Studies link lipid-lowering therapy intensification with 2 measures: lipoprotein and lipoprotein(a) testing.
Lipoprotein
upin humans1OR 1.73
1 study
Lipoprotein
upin humans1OR 1.73
Lipoprotein is associated with lipid-lowering therapy intensification in humans (compared with Lp(a) <50 mg/dL) (OR 1.73, 95% CI 1.55-1.94).
“Compared with Lp(a) <50 mg/dL, Lp(a) >50 mg/dL was associated with increased LLTI (OR, 1.73 [95% CI, 1.55-1.94]).”
Humanscompared with Lp(a) <50 mg/dL12 months
Journal of the American Heart Association
Lipoprotein(a) testing
upin humans1OR 2.11
1 study
Lipoprotein(a) testing
upin humans1OR 2.11
Lipoprotein(a) testing is associated with lipid-lowering therapy intensification in humans (OR 2.11, 95% CI 1.95-2.29).
“Lp(a) testing was associated with greater LLTI (odds ratio [OR], 2.11 [95% CI, 1.95-2.29])”
Humans12 months
Journal of the American Heart Association